APS 03118
Alternative Names: APS-03118Latest Information Update: 03 Aug 2026
At a glance
- Originator Applied Pharmaceutical Science
- Class Antineoplastics
- Mechanism of Action Proto-oncogene protein c-ret inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
- Preclinical Medullary thyroid cancer; Non-small cell lung cancer
Most Recent Events
- 29 May 2026 Efficacy and adverse events data from a phase I trial in Solid tumours presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2026)
- 05 Apr 2024 Efficacy, adverse events and pharmacodynamics data from phase-I clinical trials in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 16 Dec 2022 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable) in China (PO)(NCT05653869)